A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Brief Title

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Official Title

A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia

Brief Summary

      These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV
      infusion in one adult and one child with hypoplasminogenemia. These patients are under
      treatment to address wound healing and obstructions.
    



Study Type

Expanded Access




Condition

Hypoplasminogenemia

Intervention

Plasminogen (Human)


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological





Eligibility Criteria

        Inclusion Criteria:

          -  Patient has provided informed consent.

          -  Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as
             evidence by ligneous conjunctivitis since birth as well as involvement of the
             conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and
             urinary tract.

        Exclusion Criteria:

          -  Not applicable
      

Gender

All

Ages

16 Months - N/A


Contacts

, , 



Administrative Informations


NCT ID

NCT03265171

Organization ID

2002C013G


Responsible Party

Sponsor

Study Sponsor

Prometic Biotherapeutics, Inc.

Collaborators

 Cedars-Sinai Medical Center

Study Sponsor

, , 


Verification Date

April 2020